Cite
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.
MLA
UCL - SSS/IREC/GAEN - Pôle d’Hépato-gastro-entérologie, et al. “Bevacizumab plus Chemotherapy as Salvage Treatment in Chemorefractory Patients with Metastatic Colorectal Cancer.” OncoTargets and Therapy, Vol. 6, p. 53-58 (2013), 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1130496319&authtype=sso&custid=ns315887.
APA
UCL - SSS/IREC/GAEN - Pôle d’Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Geva, R., Vecchione, L., Tejpar, S., Piessevaux, H., Van Cutsem, E., & Prenen, H. (2013). Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. OncoTargets and Therapy, Vol. 6, p. 53-58 (2013).
Chicago
UCL - SSS/IREC/GAEN - Pôle d’Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Ravit Geva, Loredana Vecchione, Sabine Tejpar, Hubert Piessevaux, Eric Van Cutsem, and Hans Prenen. 2013. “Bevacizumab plus Chemotherapy as Salvage Treatment in Chemorefractory Patients with Metastatic Colorectal Cancer.” OncoTargets and Therapy, Vol. 6, p. 53-58 (2013). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1130496319&authtype=sso&custid=ns315887.